Annals of Clinical and Medical Case Reports

Research Article

ISSN 2639-8109 | Volume 11

Busto Covid-19 Score Identify Low Risk Patients - External Validation

Foieni F[1*], Beltrami LM[3], Sala G[3], Ughi N[3], Del Gaudio F[4], Ghiringhelli P[2] and Epis O[3]

[1]Internal Medicine, Desio Hospital – ASST Brianza, Monza-Brianza, Italy

[2]Internal Medicine, Busto Arsizio Hospital - ASST Valle Olona, Varese, Italy

[3]Division of Rheumatology, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

[4]Traning, Research and Development Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

[*]Corresponding author:

Fabrizio Foieni,
Internal Medicine, Desio Hospital, ASST Brianza (Monza-Brianza), Italy,

E-mail: fabrizio.foieni@asst-brianza.it

Received: 10 June 2023
Accepted: 26 July 2023
Published: 04 Aug 2023
J Short Name: ACMCR

Copyright:

©2023 Foieni F. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially

Citation:

Foieni F, Busto Covid-19 Score Identify Low Risk Patients - External Validation. Ann Clin Med Case Rep. 2023; V11(2): 1-6

Keywords:

Validation score; Score; Covid-19; Critical illness; Predictive-markers; Sars-CoV2

1. Abstract

1.1. Importance: Early identification of patients with Novel CoronaVirus disease (COVID-19) is an essential tool for delivering proper treatment, discharging safely patients to home and optimizing the use of available resources.

1.2. Objective: External validation of a Clinical Risk Score (Busto COVID-19 score) to predict which COVID-19 patients can be considered at low risk to develop critical illness.

Design, setting, and participants: Collaborating with Niguarda Hospital research team of Milan, we considered a retrospective cohort of COVID-19 patients admitted to this hospital from the end of February up to May 31st, 2020. Anamnestic, clinical, laboratory and imaging data collected at hospital admission were screened by data managers and dedicated medical doctors. Variables included in this retrospective cohort were analyzed to validate the Busto COVID-19 score as a Clinical Risk Score able to individuate low risk COVID-19 patients.

1.3. Main Outcomes and Measures: Among COVID-19 patients admitted to the hospital, critical illness was considered the admission to the Intensive Care Unit or death.

1.4. Results: The development cohort included 427 consecutive patients. The mean (SD) age of patients among the cohort was 60.5 years; 273 (63%) were men. As potential predictors, Busto COVID-19 score variables include: lung ultrasound abnormality, age, total white blood cells count, C-reactive protein value, pO2/FiO2 ratio, lactates value, arterial hypertension and fever from 5 days or more25. The mean AUC in the derivation sample was 0.88 (95% CI, 0.85-0.91) and the AUC in the external sample was 0.71 (95% CI, 0.64-0.78). The score has been translated into an online risk calculator that is freely available to the public (https//health-key.it).

1.5. Conclusions and Relevance: In this retrospective study, a clinical risk score based on few important characteristics of COVID-19 patients at the time of admission to the hospital was validated. Busto COVID-19 score identifies patients at low risk that may be early discharged from the hospital with an optimal use of resources. We suggest the implementation of the Busto COVID-19 score as a decision-making tool to guide the initial management of these patients.

2. Introduction

The first human cases of SARS-CoV-2 were reported in Wuhan, Hubei Province, China in January 2020[1,2]; subsequently, it spread worldwide, officially being defined as a pandemic by WHO on 11 March 2020[3-5]. Italy was the first country outside Asia to be heavily affected by the virus and the Lombardy Region had the highest burden of mortality and strain on its healthcare system [6]. However, a substantial reorganization of healthcare facilities was necessary in all Italian regions to cope with the widespread and rapid increase in COVID-19 patient flow to emergency departments.

Prompt referral to the appropriate care setting (ie, low vs intermediate or high intensity) is of crucial importance to improve outcomes and healthcare resource utilization [7-9]. Given the high number of patients to be triaged during this emergency and the relative shortage of hospital beds, the availability of a disease-specific mortality risk score since initial triage might have been useful in identifying the appropriate level of care and reducing delay. However, there is a lack of reliable prognostic prediction models and, at present, no tool for the early stratification of mortality risk has been fully identified [10]. A recent systematic review of prediction models concluded that the performance of prognostic estimates for COVID-19 may be overoptimistic and misleading, because of the high risk of bias in patient selection, unclear outcome definition and length of follow-up [10]. Recently, clinical scores to predict the occurrence of critical illness and/or fatal outcome during COVID-19 were developed in a cohort of Chinese patients belonging to more than 500 centers throughout the country [11,12]. However, these were developed in a specific region which could potentially limit the generalizability of the risk score to other areas of the world.

Therefore, the aim of the present study was to external validation a novel COVID-19 in-hospital mortality risk score (hereafter referred to as Busto score), based on data rapidly obtainable soon after hospital admission. To this end, we analyzed a consecutive series of COVID-19 patients admitted to one tertiary care hospitals located in Northern Italy.

3. Material and Methods

This study was not submitted to the Hospital Committee (Niguarda Ethics Committee) because it does not take the form of a prospective cohort study, it does not provide for the collection of biological material, it does not involve the use of experimental drugs and any external costs or sponsorships. Written Institutional informed consent about privacy and personal data management was acquired at the presentation to Hospital Emergency Room.

3.1. Patient Identification and Eligibility

We obtained the medical records and compiled data for 427 consecutive hospitalized patients with laboratory-confirmed COVID-19 from the ASST Grande Ospedale Metropolitano Niguarda (Milan - Italy) from February 28 to June 5, 2020. A confirmed case of COVID-19 was defined as a positive result on real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay of nasal-pharyngeal swab specimens [7]. Alternative respiratory specimen collection in the intubated patient included tracheal aspirates and bronchoscopy alveolar lavage.

3.2. Study Definitions

Fever was defined as an axillary temperature of 37.5°C or higher. The arterial oxygen saturation in room air (SpO2) was measured on arrival of the patient in Emergency Room with a CE certified Pulse Oximeter Fingertip and at the same time a blood gas analysis was also performed. The C-reactive protein (PCR, mg/L), Lactate dehydrogenase (LDH, U/L), White blood cell (WBC, 103/mm3) count are routine laboratory tests. The P/F ratio represents the arterial oxygen pressure (PaO2 in mmHg) to fractional inspired oxygen (FiO2 expressed as a fraction, not a percentage). The results used in the rule where the Emergency Department (ED) values not the peak values observed during the hospital stay. The ultrasound pattern was carried out in accordance with the use of lung ultrasound for COVID-19 patients proposed by Soldati G et al [19]. We defined "Wet/Interstitial syndrome" pattern when the operator highlighted B lines, pleura line broken and below the breaking point small to large, consolidated areas (score 2 and 3); "Dry/Interstitial syndrome" pattern when the pleura line was continuous, regular or indented with visible vertical areas of white below the indent (B lines). B lines reflect local alterations in the acoustical properties of the lung caused by a replacement of air by water, blood, or fibrous tissue [8-10]. Besides, if the "Wet pattern" was localized to one segment of one lung, the whole ultrasound pattern in that patient was considered "Wet". Laboratory confirmation of SARS-CoV-2 was performed at the Grande Ospedale Metropolitano Niguarda in Milan. RT-PCR assays were performed in accordance with the protocol established by the WHO [7]. We applied the rule described by Foieni et al [18-25]. We used clinical variables routinely available at presentation that were previously shown to be associated with mortality in patients with Covid-19 or other acute diseases [11]. The aim of the study is an external validation of a Clinical Risk Score (Busto COVID-19 score) to predict which COVID-19 patients can be considered at low risk to develop critical illness.

3.3. Statistical Analysis

The study cohort consists of 427 consecutive patients with COVID-19 admitted to the same hospital. A clustering of the scores divided patients into four specific groups (group 1, group 2, group 3, group 4). In order to assess the discriminatory power that the model has to predict outcomes, the study presents a comparison between groups from derivation and external validation sample. To assess the reliability of the model regardless of random sampling errors, we performed independent sample T-Test, comparing the scores mean of each group among our independent samples. Moreover, we got ROC curves to evaluate the area under the curves (AUC) of each sample, considering the outcome "In-hospital mortality" as the state variable. All the analyses have been performed making use of Microsoft Excel 2016 and IBM SPSS Software

4. Results

427 patients with COVID-19 were included in the external validation sample. Most patients were men (273-63%), with a mean age of 60.5 years (4-99) and 191 (45%) patients suffered from Arterial Hypertension (Table 1); in both samples, the average value of lactates, the P/F index and LDH was not very different; the CRP value of the derivation sample is higher than the external validation

sample (12.8 mg/dL vs 8.2 mg/dL). The weighted variables of the score system is illustrated in (Table 2). The prediction rule identified similar populations with a comparable score mean in each of the four groups across the derivation and external validation sample (Table 3,4).

We point out that 2 patients of group 1 were admitted to the ICU; they actually featured a discrepancy between pulmonary ultrasound (dry- interstitial syndrome without consolidations) and thoracic CT (severe interstitial pneumonia with subpleural consolidation). However, we state that in the first group it has not been registered people that died (Figure 1). The rule's discriminatory power for mortality was similar in the derivation and external validation samples, with an area under the receiver operating characteristic curve (ROC curve) of 0,90 (CI95% 0,801-0,982) and 0,71 (CI95% 0,64-0,78), respectively (Figure 2). The test proved to be not very sensitive but with a high specificity (98%). This can be explained by the fact that in all identified groups there may be patients discharged, but no progression to an unfavourable outcome for the patients who are stratified in group 1.

Table 1: Baseline patient characteristics in the derivation and external validation samples

Patients Characteristics *	Derivation samples (n=79)	External samples (n=427)
Age (min-max, mean)	31-91 (66.8)	4-99 (60.5)
Male sex (%)	54 (68%)	273 (63%)
Hypertension (%)	56 (70%)	191 (45%)
Temperature >37.5 (%)	65 (82%)	348 (81.4%)
Pulmonary pattern "Wet" (%)	28 (35%)	176 (41.2%)
Respiratory rate (min-max, mean, median)	15-48 (26;24)	12-40 (22;20)
Arterial oxygen saturation (min-max, mean, median)	63-96 (88;88)	54-100 (94;95)
Absolute White blood cell count (103/mm3) (min-max, mean, median)	1.1-16.1 (8.06;7.06)	1.51-66.5 (7.64, 6.78)
CRP (mg/L) (min-max, mean, median)	0.1-41 (12.8;11)	0.1-38.60 (8.21, 6.70)
LDH (U/L) (min-max, mean, median)	87-1602 (504;420)	130-677 (336;320)
BMI (kg/m2) (min-max, mean, median)	18.4-37 (26;26)	16-50 (28;27)
P/F Ratio (min-max, mean, median)	50-460 (243;252)	51-505 (288,304)
Lactates (mg/dL) (min-max, mean, median)	2.3-47.7 (13.78;11)	4.3-87.1(14.18, 11.70)

Note 1: CRP, C-reactive protein; LDH, lactate dehydrogenase; P/F ratio, the arterial oxygen pressure divided by the FIO2 (the fraction of inspired oxygen expressed as a decimal); BMI, Body Mass Index.

Table 2: Multivariable predictors of outcomes in the Busto COVID-19 score

Variables	ß-coefficients	95%CI	pValue
Fever for more than 5 days	0,219	-0,15 - 0,59	0,24
Hypertension	0,194	-0,12 - 0,51	0.22
Pattern US "Wet"	0,731	0,42 - 1,03	<0,001
P/F ratio	0,002	0,00 - 0,003	0,02
Lactates (mg/dL)	0,041	0,02 - 0,06	<0,001
WBC (G/L)	-0,022	-0,07 - 0,02	0.36
CRP (mg/dL)	0,019	0,00 – 0,03	0.02
Age	0,014	0,00 – 0,02	0.02

Table 3: Groups based on Busto score applied to external samples

Medical Outcomes	Group 1	Group 2	Group 3	Group 4	Total
Discharged (outcome 1)	62	115	101	28	306
Admitted to ICU (outcome 2)	2*	30	30	11	73
Exitus (outcome 3)	0	11	21	16	48
Total samples	64	156	152	55	427

* Hight discrepancy between ultrasound (negative) and CT (whit large and bilateral consolidations)

Table 4: Risk class-specific medical outcomes in the derivation, validation samples and external samples

Medical Outcomes	Derivation sample (n=79)	Validation sample (n=40)	External samples (n=427)	pValue
Discharged	52 (66% of the sample)	30 (75% of the sample)	308 (72% of the sample)	0.47
Group 1	12 (100%)	5 (100%)	62 (97%)	
Group 2	28 (84%)	11 (69%)	115 (73%)	
Group 3	11 (55%)	12 (85%)	101 (66%)	
Group 4	1(7%)	2 (40%)	28 (51%)	
Admittend in ICU	9 (11% of the sample)	4 (10% of the sample)	73 (17% of the sample)	0.44
Group 1	0%	0%	2*(3%)	
Group 2	3 (9%)	3 (18,75%)	30 (19%)	
Group 3	5 (25%)	1 (7%)	30 (20%)	
Group 4	1 (7%)	0%	11 (20%)	
Exitus	18 (23% of the sample)	6 (15% of the sample)	48 (11% of the sample)	0.44
Group 1	0%	0%	0%	
Group 2	2(6%)	2 (12,5%)	11 (7%)	
Group 3	4(20%)	1 (7%)	21 (14%)	
Group 4	12(86%)	3 (60%)	16 (29%)	

* Hight discrepancy between ultrasound (negative) and CT (whit large and bilateral consolidations)



Figure 1: ROC curves of the derivation (A) and external sample (B) about the outcome "Exitus".



Figure 2: In the first Group are not dead people (outcome 3)

5. Discussion

The first and secondary COVID-19 outbreak put high pressure on Lombardy healthcare services. To prioritize resources for patients with the highest risk mortality, we developed a clinical prediction rule for prognosis of COVID-19 patients and a calculator to allow clinicians to calculate the likelihood (with 95% CI) that a hospitalized patient could develop critical illness. The performance of the rule was reliable, but its clinical use involved its validation on an external population. In the derivation and external validation samples, we didn't observe any significant difference between risk groups considering specific mortality, ICU admission and discharge. Our rule accurately identifies patients who are at low risk of fatal medical outcomes: group 1 and group 2 patients respectively had 0.4% and 7% or less admission in ICU, 0% and 2% in-hospital mortality. Our rule can provide clinicians with an explicit tool to identifying low-risk patients with COVID-19 who might be potential candidates for outpatient treatment or early hos-

pital discharge. Group 4 confirmed a high rate of ICU admissions and mortality rate (20% e 29% respectively). Furthermore, we observed a significant reduction in ICU admissions and mortality in both group 3 and group 4 compared to the previous study of deriving the score [25]. It could likely be the sign of systematic use of the steroid [26, 27] and heparin. The intermediate groups (groups 2 and 3) are the most numerous and probably correspond to the overlap subset identified by the Siddiki model [11-17]. We believe that this is probably the point where an adequate therapeutic approach can interrupt a process that leads to severe hyperinflammatory syndrome. The study produced in China by Zhou et al [31] proposed a predictive model for the severity of COVID-19 using age, neutrophil / lymphocyte ratio, CRP and D-Dimer as variables. The proposed model resulted in a negative predictive value of 0.93, a positive predictive value of 0.41, a specificity of 0.70 and a sensitivity of 0.89. Ageno et al [32] recently produced a 6-variable score (SIMI score) starting from the variables proposed by Zhou with the addition of the anamnestic data of chronic ischemic heart disease (CHD) and the value of alanine aminotransferase (ALT). This retrospective and observational study takes into consideration data from a multicenter registry promoted by the Italian Society of Internal Medicine a database made up of 5 centers in northern Italy. Despite the excellent statistical analysis, the generic variables used not associated with lung imaging leads to an overestimation of an unfavorable outcome. It is not difficult for many COVID-19 patients to reach a value of 7 as the score suggests. Furthermore, this study does not envisage a validation of the score on a dataset outside the register. In a larger study from Liang et al [24] including 1590 patients for the derivation set and 710 patients for the validation set, 10 variables were identified as independent predictive factors for adverse outcome (admission to the Intensive Care Unit, need for invasive ventilation and death). This study developed an online calculator to enter the values of 10 variables including X-ray pattern. Our specific experience allowed us to use, instead of the X-ray pattern, the easier disposable and user-friendly ultrasound tool. Moreover, the Busto Covid-19 score has the advantage of the use of fewer variables, which potentially makes it suitable for daily clinical practice. We also believe that the real challenge in approaching the COVID-19 patient is to identify patients who can be managed in facilities outside the hospital or at home. In this way, hospital resources are preserved for patients with more compromised clinical pictures. The Busto score brings together anamnestic, laboratory and imaging variables and identified a series of patients who could be managed outside the hospital. We suggest a practical tool easy to use even in Emergency Room for risk stratification that classifies patients with COVID-19 at increasing risk of death and other adverse outcomes. It can improve outpatient management and early hospital discharge of patients with COVID-19 identified as low risk (group 1 and group 2) with large cost savings without added risk. The dataset from the Grande Ospedale Metropolitano Niguarda of Milan confirmed the results of our previous experience.

6. Conclusion

The Busto Covid-19 score identifies COVID-19 patients with low risk of in-hospital mortality and admission to intensive care unit (ICU). Moreover, it establishes an intermediate portion of patients that should be treated accurately to avoid an unfavorable clinical evolution.

7. Author Contributions

F.Foieni, G.Sala and N.Ughi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

8. Concept and Design

F.Foieni, G.Sala, N.Ughi.

9. Acquisition, Analysis, or Interpretation of Data

LM Beltrami, Gaudio F., N.Ughi.

10. Drafting of the Manuscript

F.Foieni, G.Sala, LM Beltrami.

11. Critical Revision of the Manuscript

F.Foieni, P.Ghiringhelli, O.Epis.

12. Statistical Analysis

Federico Foieni.

13. Administrative, Technical, or Material Support

LM Beltrami.

14. Conflict of Interest Disclosures

None reported.

15. Memorial

This work was made in order to remind people of health care workers who gave their lives in the care of COVID-19 patients.

16. Acknowledgement

Special thanks to all those who have supported us and given some of their time to produce this work.

References

1. Morens DM, Daszak P, Taubenberger JK. Escaping Pandora's box—another novel coronavirus. N Engl J Med. 2020; 382(14): 1293-1295.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382: 727-733.
3. Worldometer. COVID-19 coronavirus pandemic. April 2, 2020.
4. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145–51.
5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease

Control and Prevention. JAMA. 2020; 323(13): 1239-1242.

6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46(5): 846-848.
7. World Health Organization. Coronavirus disease (COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans.
8. Huang, Y, Wang S, Liu Y. A preliminary study on the ultrasonic manifestations of peripulmonary lesions of non-critical novel coronavirus pneumonia (COVID-19). SSRN. 2020.
9. Smith MJ, Hayward SA, Innes SM, Miller ASC. Point-of-care lung ultrasound in patients with COVID-19 - a narrative review. Anaesthesia. 2020; 75(8): 1096-1104.
10. Winkler M, Touw H, Van de Ven P, Twisk J, Tuinman PR. Diagnostic accuracy of chest radiograph, and when concomitantly studied lung ultrasound, in critically ill patients with respiratory symptoms: a systematic review and meta-analysis. Critical Care Medicine. 2018; 46: e707–e714.
11. Henry BM, De Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7): 1021-1028.
12. Gattinoni l, Chiumello D, Caironi P. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Med. 2020; 46(6): 1099-1102.
13. Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020; 323(22): 2329-2330.
14. Matthay AM, Aldrich JM, Gotts JE. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respir Med. 2020.
15. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance. January 28, 2020.
16. Sanders JM, Monogue ML, Jodlowsky TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-2019). A Rewiew. JAMA. 2020; 323(18): 1824-1836.
17. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Heart Lung Transplant. 2020; 39(5): 405-407.
18. Yan L, Zhang, H, Goncalves J. An interpretable mortality prediction model for COVID-19 patients. Nat Mach Intell 2. 2020; 283–288.
19. Soldati G. Lung Ultrasound in COVID Patients. Proposal for international standardization of the use of lung ultrasound for COVID-19 patients; a simple, quantitative, reproducible method. J Ultrasound Med. 2020; 39(7):1413-1419.
20. Wynants L, Van Calster B, Bonten MMJ. Prediction models for diagnosis and prognosis of covid-19 infection: Sistematic review and critical appraisal. BMJ. 2020; 369.
21. Leidi F, Casella F, Cogliati C. Bedside lung ultrasound in the evaluation of acute decompesated heart failure. Intern Emerg Med. 2016; 11(4):597-601.
22. Trezzi m, Torzillo D, Ceriani E. Lung ultrasonography for the assessment of rapid extravascular water variation: Evidence from haemodialysis patients. Inten Emerg Med. 2013; 8(5):409-15.
23. Volpicelli G, Mussa A, Garofalo G. Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome. Am J Emerg Med. 2006; 24(6): 689-96.
24. Liang W, Liang H, Ou L. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020; 180(8): 1081-1089.
25. Foieni F, Sala G, Mognarelli J. Derivation and validation of the clinical prediction model for COVID-19. Intern Emerg Med. 2020; 15: 1409-1414.
26. Whitty C. Dexamethasone in the treatment of COVID-19: Implementation and management of supply for treatment in hospitals. London: Medicines and Healthcare Products Regulatory Agency, 2020.
27. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med. 2020; 384(8):693-704.
28. Ji D, Zhang D, Xu J. Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score. Clin Infect Dis. 2020; 71(6): 1393-1399.
29. Bello-Chavolla OY, Bahena-López JP. Predicting Mortality Due to SARS-CoV-2: A Mechanistic Score Relating Obesity and Diabetes to COVID-19 Outcomes in Mexico. J Clin Endocrinol Metab. 2020; 105(8):dgaa346.
30. Hu H, Du H, Li J, Wang Y. Early prediction and identification for severe patients during the pandemic of COVID-19: A severe COVID-19 risk model constructed by multivariate logistic regression analysis. J Glob Health. 2020; 10(2):020510.
31. Zhou Y, Yang Z, Guo Y. A new predictor of disease severity in patients with COVID-19 in Wuhan, China. MedRxiv. 2020.